315 related articles for article (PubMed ID: 29186350)
1. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
Holley RJ; Ellison SM; Fil D; O'Leary C; McDermott J; Senthivel N; Langford-Smith AWW; Wilkinson FL; D'Souza Z; Parker H; Liao A; Rowlston S; Gleitz HFE; Kan SH; Dickson PI; Bigger BW
Brain; 2018 Jan; 141(1):99-116. PubMed ID: 29186350
[TBL] [Abstract][Full Text] [Related]
2. Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB.
Zheng Y; Ryazantsev S; Ohmi K; Zhao HZ; Rozengurt N; Kohn DB; Neufeld EF
Mol Genet Metab; 2004 Aug; 82(4):286-95. PubMed ID: 15308126
[TBL] [Abstract][Full Text] [Related]
3. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease.
Sergijenko A; Langford-Smith A; Liao AY; Pickford CE; McDermott J; Nowinski G; Langford-Smith KJ; Merry CL; Jones SA; Wraith JE; Wynn RF; Wilkinson FL; Bigger BW
Mol Ther; 2013 Oct; 21(10):1938-49. PubMed ID: 23748415
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector.
Di Natale P; Di Domenico C; Gargiulo N; Castaldo S; Gonzalez Y Reyero E; Mithbaokar P; De Felice M; Follenzi A; Naldini L; Villani GR
Biochem J; 2005 Jun; 388(Pt 2):639-46. PubMed ID: 15649123
[TBL] [Abstract][Full Text] [Related]
5. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
[TBL] [Abstract][Full Text] [Related]
6. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
[TBL] [Abstract][Full Text] [Related]
7. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB.
Di Domenico C; Villani GR; Di Napoli D; Nusco E; Calì G; Nitsch L; Di Natale P
Am J Med Genet A; 2009 Jun; 149A(6):1209-18. PubMed ID: 19449420
[TBL] [Abstract][Full Text] [Related]
8. Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome.
Gougeon ML; Poirier-Beaudouin B; Ausseil J; Zérah M; Artaud C; Heard JM; Deiva K; Tardieu M
Front Immunol; 2021; 12():655478. PubMed ID: 34040605
[TBL] [Abstract][Full Text] [Related]
9. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
[TBL] [Abstract][Full Text] [Related]
10. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery.
Fu H; Samulski RJ; McCown TJ; Picornell YJ; Fletcher D; Muenzer J
Mol Ther; 2002 Jan; 5(1):42-9. PubMed ID: 11786044
[TBL] [Abstract][Full Text] [Related]
11. The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.
Schiattarella GG; Cerulo G; De Pasquale V; Cocchiaro P; Paciello O; Avallone L; Belfiore MP; Iacobellis F; Di Napoli D; Magliulo F; Perrino C; Trimarco B; Esposito G; Di Natale P; Pavone LM
PLoS One; 2015; 10(7):e0131662. PubMed ID: 26147524
[TBL] [Abstract][Full Text] [Related]
12. Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice.
Clarke D; Pearse Y; Kan SH; Le SQ; Sanghez V; Cooper JD; Dickson PI; Iacovino M
Mol Ther Methods Clin Dev; 2018 Sep; 10():113-127. PubMed ID: 30101150
[TBL] [Abstract][Full Text] [Related]
13. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency.
Lotfi P; Tse DY; Di Ronza A; Seymour ML; Martano G; Cooper JD; Pereira FA; Passafaro M; Wu SM; Sardiello M
Autophagy; 2018; 14(8):1419-1434. PubMed ID: 29916295
[TBL] [Abstract][Full Text] [Related]
14. Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC.
Pan X; Caillon A; Fan S; Khan S; Tomatsu S; Pshezhetsky AV
Cells; 2024 May; 13(10):. PubMed ID: 38786099
[TBL] [Abstract][Full Text] [Related]
15. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
Ribera A; Haurigot V; Garcia M; Marcó S; Motas S; Villacampa P; Maggioni L; León X; Molas M; Sánchez V; Muñoz S; Leborgne C; Moll X; Pumarola M; Mingozzi F; Ruberte J; Añor S; Bosch F
Hum Mol Genet; 2015 Apr; 24(7):2078-95. PubMed ID: 25524704
[TBL] [Abstract][Full Text] [Related]
16. A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.
Ellinwood NM; Wang P; Skeen T; Sharp NJ; Cesta M; Decker S; Edwards NJ; Bublot I; Thompson JN; Bush W; Hardam E; Haskins ME; Giger U
J Inherit Metab Dis; 2003; 26(5):489-504. PubMed ID: 14518829
[TBL] [Abstract][Full Text] [Related]
17. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
[TBL] [Abstract][Full Text] [Related]
18. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
Tardieu M; Zérah M; Gougeon ML; Ausseil J; de Bournonville S; Husson B; Zafeiriou D; Parenti G; Bourget P; Poirier B; Furlan V; Artaud C; Baugnon T; Roujeau T; Crystal RG; Meyer C; Deiva K; Heard JM
Lancet Neurol; 2017 Sep; 16(9):712-720. PubMed ID: 28713035
[TBL] [Abstract][Full Text] [Related]
19. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient.
Vallejo-Diez S; Fleischer A; Martín-Fernández JM; Sánchez-Gilabert A; Bachiller D
Stem Cell Res; 2018 Dec; 33():180-184. PubMed ID: 30408744
[TBL] [Abstract][Full Text] [Related]
20. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.
Fu H; Dirosario J; Killedar S; Zaraspe K; McCarty DM
Mol Ther; 2011 Jun; 19(6):1025-33. PubMed ID: 21386820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
